Emmaus Life Sciences, Inc. (EMMA)

0.1000 +0.0079 (+8.57%) At close: 03:42PM EDT

Emmaus Life Sciences, Inc.

21250 Hawthorne Boulevard
Suite 800
Torrance, CA 90503
United States
310 214 0065
https://www.emmausmedical.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 54

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Willis C. Lee M.S.	Co-President, COO & Chairman of the Board	240k	N/A	1960
Mr. Yasushi Nagasaki CPA, CPA	Chief Financial Officer	250k	N/A	1967
Mr. George Sekulich	Co-President, Chief Commercial Officer & Director	N/A	N/A	1966
Mr. Dale E. Short J.D.	Legal Consultant & Corporate Secretary	N/A	N/A	N/A
Dr. Charles W. Stark Pharm.D, Pharm.D.	Senior Vice President of Medical Affairs, Clinical, Regulatory	N/A	N/A	1955
Mr. Kurt H. Kruger M.B.A., M.S.	Consultant	300.02k	N/A	1955

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Corporate Governance

Emmaus Life Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.